Information  X 
Enter a valid email address

GlaxoSmithKline PLC (GSK)

  Print      Mail a friend       Annual reports

Wednesday 15 January, 2020

GlaxoSmithKline PLC

Director/PDMR Shareholding

RNS Number : 8051Z
GlaxoSmithKline PLC
14 January 2020
 

GlaxoSmithKline plc (the 'Company')

Transaction notification

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms E Walmsley

b)

Position/status

Chief Executive Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 9 January 2020 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.

c)

Price(s) and volume(s)


Price(s)

Volume(s)



£17.9020

195



£17.9020

195



£17.9020

684



£17.9020

680






d)

Aggregated information

 

1,754

Aggregated volume Price

£17.9020

e)

Date of the transaction

2020-01-13

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr R Connor     

 

b)

Position/status

President, Global Vaccines

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 9 January 2020 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.

c)

Price(s) and volume(s)


Price(s)

Volume(s)



£17.9020

101



£17.9020

101



£17.9020

144



£17.9020

178






d)

Aggregated information

 

524

Aggregated volume Price

£17.9020

e)

Date of the transaction

2020-01-13

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr N Hirons

b)

Position/status

SVP, Global Ethics & Compliance

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 9 January 2020 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.

c)

Price(s) and volume(s)


Price(s)

Volume(s)



£17.9020

64



£17.9020

64



£17.9020

75



£17.9020

74






d)

Aggregated information

 

277

Aggregated volume Price

£17.9020

e)

Date of the transaction

2020-01-13

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr L Miels

b)

Position/status

President, Global Pharmaceuticals

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 9 January 2020 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.

c)

Price(s) and volume(s)


Price(s)

Volume(s)



£17.9020

137



£17.9020

190






d)

Aggregated information

 

327

Aggregated volume Price

£17.9020

e)

Date of the transaction

2020-01-13

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr D Redfern

b)

Position/status

Chief Strategy Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 9 January 2020 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.

c)

Price(s) and volume(s)


Price(s)

Volume(s)



£17.9020

80



£17.9020

80



£17.9020

140



£17.9020

168






d)

Aggregated information

 

468

Aggregated volume Price

£17.9020

e)

Date of the transaction

2020-01-13

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr R Simard

b)

Position/status

President, Pharmaceuticals Supply Chain

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 9 January 2020 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.

c)

Price(s) and volume(s)


Price(s)

Volume(s)



£17.9020

61






d)

Aggregated information

 

N/A (single transaction)

Aggregated volume Price


e)

Date of the transaction

2020-01-13

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr P Thomson

b)

Position/status

President, Global Affairs

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 9 January 2020 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.

c)

Price(s) and volume(s)


Price(s)

Volume(s)



£17.9020

76



£17.9020

95



£17.9020

98






d)

Aggregated information

 

269

Aggregated volume Price

£17.9020

e)

Date of the transaction

2020-01-13

f)

Place of the transaction

 

London Stock Exchange (XLON)

 



 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr B McNamara

b)

Position/status

CEO, GSK Consumer Healthcare

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares ('ADSs')

ISIN: US37733W1053

 

b)

Nature of the transaction

Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 9 January 2020 on ADSs held in the Company's Deferred Annual Bonus Plan.

c)

Price(s) and volume(s)


Price(s)

Volume(s)



$46.6500

74



$46.6500

72



$46.6500

68










d)

Aggregated information

 

214

Aggregated volume Price

$46.6500

e)

Date of the transaction

2020-01-13

f)

Place of the transaction

 

New York Stock Exchange (XNYS)

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Dr H Barron

b)

Position/status

Chief Scientific Officer and President, R&D

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares ('ADSs')

ISIN: US37733W1053

 

b)

Nature of the transaction

Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 9 January 2020 on ADSs held in the Company's Deferred Annual Bonus Plan.

c)

Price(s) and volume(s)


Price(s)

Volume(s)



$46.6500

406






d)

Aggregated information

 

N/A (single transaction)

Aggregated volume Price


e)

Date of the transaction

2020-01-13

f)

Place of the transaction

 

New York Stock Exchange (XNYS)

 

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr J Ford

b)

Position/status

Senior Vice President and General Counsel

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares ('ADSs')

ISIN: US37733W1053

 

b)

Nature of the transaction

Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 9 January 2020 on ADSs held in the Company's Deferred Annual Bonus Plan.

c)

Price(s) and volume(s)


Price(s)

Volume(s)



$46.6500

35






d)

Aggregated information

 

N/A (single transaction)

Aggregated volume Price


e)

Date of the transaction

2020-01-13

f)

Place of the transaction

 

New York Stock Exchange (XNYS)

 

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms K Terrell

b)

Position/status

Chief Digital & Technology Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares ('ADSs')

ISIN: US37733W1053

 

b)

Nature of the transaction

Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 9 January 2020 on ADSs held in the Company's Deferred Annual Bonus Plan.

c)

Price(s) and volume(s)


Price(s)

Volume(s)



$46.6500

24



$46.6500

86






d)

Aggregated information

 

110

Aggregated volume Price

$46.6500

e)

Date of the transaction

2020-01-13

f)

Place of the transaction

 

New York Stock Exchange (XNYS)

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
DSHVZLFFBFLXBBE

a d v e r t i s e m e n t